Assessing Epcoritamab for Adult Patients with Advanced Lymphoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the real-world effectiveness of subcutaneous epcoritamab in adults diagnosed with advanced diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Approximately 700 participants will be enrolled across 80 sites in 12-20 countries, receiving treatment as prescribed by their physicians. Participants will be monitored for up to three years, attending regular visits at their healthcare facilities without additional burdens related to the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL).
* Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country.
* The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study.

Exclusion Criteria:

* Any condition included in the contraindications section of the approved local epcoritamab label in the participating country.
* Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study.

Where it's running

• Hospital Britanico de Buenos Aires /ID# 274419
  Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina Recruiting
• Hospital Universitario Austral /ID# 274393
  Pilar, Buenos Aires, Argentina Recruiting
• Instituto Alexander Fleming /ID# 277284
  Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina Recruiting
• Hospital Privado Universitario De Córdoba /ID# 274457
  Córdoba, Córdoba Province, Argentina Recruiting
• Hospital Italiano de Buenos Aires /ID# 274418
  Buenos Aires, Argentina Recruiting
• Fundacion Argentina contra la Leucemia (FUNDALEU) /ID# 274390
  Buenos Aires, Argentina Recruiting

+23 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Rebekah Taylor
• Email: rebekah.taylor@abbvie.com
• Phone: (847) 937-8000

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Non-Hodgkin Lymphoma Sample Collection for MRD Testing

  This study tests a blood-based and tissue-based approach to see if a molecular residual disease test can detect lingering cancer in adults with aggressive NHL who are starting standard therapy.

  Recruiting Natera, Inc. · Austin, Texas · NCT07750886

• Rituximab and Tafasitamab with Allogeneic NK Cells for relapsed or refractory B-cell NHL

  This trial tests whether giving allogeneic NK cells with Rituximab, Tafasitamab, and IL-2 can help people with relapsed or refractory B-cell non-Hodgkin lymphoma who have tried at least two prior therapies.

  Recruiting Phase 1 Case Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT07225439

• Evaluating vaccine responses in patients with multiple myeloma and non-Hodgkin lymphoma after CAR-T treatment

  This study tests how well vaccines work in people with multiple myeloma and non-Hodgkin lymphoma after they have received CAR-T treatment.

  Recruiting OHSU Knight Cancer Institute · Portland, Oregon · NCT06784167

• Combination treatment for relapsed or refractory follicular lymphoma

  This study is testing a new combination of three medications to see if it can help people with relapsed or refractory follicular lymphoma feel better.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT06563596

• Preventing CAR-T cell toxicities with emapalumab

  This study is testing if a drug called emapalumab can help prevent side effects in people with large B-cell non-Hodgkin's lymphoma who are receiving another treatment called axicabtagene ciloleucel.

  Recruiting Phase 2 Massachusetts General Hospital · Boston, Massachusetts and 1 other locations · NCT06550141

• Treatment for relapsed or refractory B-cell lymphoma using SynKIR-310

  This study is testing a new treatment called SynKIR-310 to see if it can help adults with relapsed or refractory B-cell lymphoma feel better.

  Recruiting at 5 sites Phase 1 Verismo Therapeutics · Denver, Colorado and 4 other locations · NCT06544265

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.